Pacific Edge chief executive David Darling said before the shareholders' annual meeting they would be updated on the successes of the past year, such as the company's Dunedin laboratory validation and opening, patents and licences issued and fund-raising efforts to date.
"Key to us for the year ahead is business strategies for the United States market," Mr Darling said.
Pacific Edge held its annual meeting for shareholders at the University of Otago's Centre for Innovation yesterday.
Pacific Edge is seeking to raise $16 million through a renounceable entitlement offer to eligible shareholders, and those funds, together with the proceeds of a an earlier $5.1 million share placement, would be used to commercialise its CxBladder product.
Earlier this week, Pacific Edge said it had been awarded a Singaporean patent for its colorectal cancer prognostic technology, and expected the atent would be issued in other targeted countries during the next 12 to 24 months.
In May, Health Minister Tony Ryall opened a $500,000 specialist diagnostic laboratory at Pacific Edge's base within the Centre for Innovation at Otago University.
• In trading for the year ended March, Pacific Edge booked an after-tax loss of $3.12 million, compared to a loss the year before of $2.52 million. Its six-monthly report is due in late September.
